SG11201407397WA - Formulations and methods for vaginal delivery of antiprogestins - Google Patents
Formulations and methods for vaginal delivery of antiprogestinsInfo
- Publication number
- SG11201407397WA SG11201407397WA SG11201407397WA SG11201407397WA SG11201407397WA SG 11201407397W A SG11201407397W A SG 11201407397WA SG 11201407397W A SG11201407397W A SG 11201407397WA SG 11201407397W A SG11201407397W A SG 11201407397WA SG 11201407397W A SG11201407397W A SG 11201407397WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- antiprogestins
- woodlands
- rule
- methods
- Prior art date
Links
- 208000034423 Delivery Diseases 0.000 title abstract 3
- 239000003418 antiprogestin Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000009677 vaginal delivery Effects 0.000 title abstract 3
- 230000000708 anti-progestin effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229920001218 Pullulan Polymers 0.000 abstract 1
- 239000004373 Pullulan Substances 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229960003387 progesterone Drugs 0.000 abstract 1
- 239000000186 progesterone Substances 0.000 abstract 1
- 235000019423 pullulan Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261653674P | 2012-05-31 | 2012-05-31 | |
| PCT/US2013/043447 WO2013181449A1 (en) | 2012-05-31 | 2013-05-30 | Formulations and methods for vaginal delivery of antiprogestins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407397WA true SG11201407397WA (en) | 2014-12-30 |
Family
ID=48614182
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201704858PA SG10201704858PA (en) | 2012-05-31 | 2013-05-30 | Formulations and methods for vaginal delivery of antiprogestins |
| SG11201407397WA SG11201407397WA (en) | 2012-05-31 | 2013-05-30 | Formulations and methods for vaginal delivery of antiprogestins |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201704858PA SG10201704858PA (en) | 2012-05-31 | 2013-05-30 | Formulations and methods for vaginal delivery of antiprogestins |
Country Status (22)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| WO2015171319A1 (en) | 2014-05-05 | 2015-11-12 | Repros Therapeutics Inc. | Formulations and methods for vaginal delivery of antiprogestins |
| JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． | 天然の併用ホルモン補充療法剤及び療法 |
| US11623008B2 (en) | 2014-08-20 | 2023-04-11 | Professional Compounding Centers Of America | Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan |
| WO2016064873A1 (en) * | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| EP3025709B1 (en) | 2014-11-27 | 2020-09-30 | Capsugel Belgium NV | Dosage form articles for external mucosal applications |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| JP2019513709A (ja) | 2016-04-01 | 2019-05-30 | セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． | ステロイドホルモン薬学的組成物 |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| CN110678170A (zh) * | 2017-04-14 | 2020-01-10 | 比利时胶囊公司 | 普鲁兰多糖胶囊 |
| AU2018253392B2 (en) | 2017-04-14 | 2023-11-02 | Capsugel Belgium Nv | Process for making pullulan |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2377418A1 (fr) | 1977-01-13 | 1978-08-11 | Roussel Uclaf | Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments |
| FR2521565B1 (fr) | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
| FR2522328B1 (fr) | 1982-03-01 | 1986-02-14 | Roussel Uclaf | Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments |
| FR2534487B1 (fr) | 1982-10-15 | 1988-06-10 | Dior Christian Parfums | Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede |
| DE3237814A1 (de) * | 1982-10-12 | 1984-04-12 | Warner-Lambert Co., 07950 Morris Plains, N.J. | Wasserfreie emulsionen und verwendung derselben |
| US4615697A (en) | 1983-11-14 | 1986-10-07 | Bio-Mimetics, Inc. | Bioadhesive compositions and methods of treatment therewith |
| FR2598421B1 (fr) | 1986-05-06 | 1988-08-19 | Roussel Uclaf | Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant |
| US4954490A (en) | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
| US5077211A (en) | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| US5468741A (en) | 1993-05-28 | 1995-11-21 | The Regents Of The University Of California | Use of low levels of mifepristone to treat leiomyomata |
| US5543150A (en) | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
| IL112778A0 (en) * | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| DE4426601A1 (de) | 1994-07-27 | 1996-02-01 | Schering Ag | Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri |
| SK282570B6 (sk) | 1995-02-02 | 2002-10-08 | Schering Aktiengesellschaft | Antagonisty progesterónu na výrobu liekov na ošetrenie dysfunkčného maternicového krvácania |
| GB9522403D0 (en) * | 1995-11-01 | 1996-01-03 | Hoechst Roussel Ltd | Intravaginal drug delivery device |
| US6900193B1 (en) | 1996-05-01 | 2005-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
| CA2253673C (en) | 1996-05-01 | 2009-09-08 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | 21-substituted progesterone derivatives as new antiprogestational agents |
| AU2805397A (en) | 1996-08-30 | 1998-03-19 | Population Council, Center For Biomedical Research, The | Vaginal application mifepristone |
| US6682174B2 (en) | 1998-03-25 | 2004-01-27 | Silverbrook Research Pty Ltd | Ink jet nozzle arrangement configuration |
| US20050070516A1 (en) | 1997-10-28 | 2005-03-31 | Vivus Inc. | As-needed administration of an androgenic agent to enhance female desire and responsiveness |
| US6020328A (en) | 1998-03-06 | 2000-02-01 | Research Triangle Institute | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| EP1008443A1 (de) | 1998-12-08 | 2000-06-14 | Alusuisse Technology & Management AG | Sterilisierbarer Folienverbund für Verpackungszwecke |
| US6740645B1 (en) | 1999-09-03 | 2004-05-25 | Research Triangle Institute | 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties |
| AR025609A1 (es) * | 1999-09-13 | 2002-12-04 | Hoffmann La Roche | Formulaciones lipidas solidas |
| UA74168C2 (uk) | 1999-10-05 | 2005-11-15 | Коламбіа Леборетеріс (Бермуда) Лімітед | Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу |
| EP2348031B9 (en) | 2000-03-17 | 2016-08-10 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | 17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienediones as antiprogestational agents |
| IN191020B (enrdf_load_stackoverflow) | 2000-03-28 | 2003-09-13 | Dabur Res Foundation | |
| CA2423017C (en) | 2000-10-18 | 2009-01-06 | Schering Aktiengesellschaft | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases |
| DK1411916T3 (da) | 2001-07-09 | 2008-12-15 | Repros Therapeutics Inc | Fremgangsmåder og materialer til behandling af testosteronmangel hos mænd |
| JP2005507874A (ja) | 2001-08-29 | 2005-03-24 | ユーエムディー， インコーポレイテッド | 癌治療のための化学療法剤及び膜流出システム阻害剤の経膣送達 |
| JP2003143474A (ja) | 2001-11-02 | 2003-05-16 | Matsushita Electric Ind Co Ltd | 映像信号処理システム |
| US7417013B2 (en) | 2002-05-01 | 2008-08-26 | Mcneil-Ppc, Inc. | Warming and nonirritating lubricant compositions and method of comparing irritation |
| ATE461681T1 (de) | 2003-04-29 | 2010-04-15 | Gen Hospital Corp | Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln |
| EP1593376A1 (en) * | 2004-05-04 | 2005-11-09 | Warner-Lambert Company LLC | Improved pullulan capsules |
| PT1768625E (pt) | 2004-07-09 | 2011-04-18 | Hra Pharma Lab | Composições de libertação sustida contendo moduladores do receptor da progesterona |
| GT200500185A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| CN101163467B (zh) | 2005-03-22 | 2012-07-18 | 雷普罗斯治疗公司 | 反式氯米芬的制药用途 |
| EP1874732A1 (en) | 2005-04-20 | 2008-01-09 | Pfizer Limited | Pyrazole derivatives as progesterone receptor antagonists |
| DE102005030294A1 (de) | 2005-06-24 | 2007-01-04 | Schering Ag | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| CN101316595A (zh) * | 2005-09-29 | 2008-12-03 | 利普生物药剂公司 | 具有改善生物利用度的包含甾族化合物衍生物和聚乙二醇化甘油酯的制剂 |
| CN1846703A (zh) | 2006-02-13 | 2006-10-18 | 程定超 | 米非司酮阴道给药制剂及其组成和制备方法 |
| US8173626B2 (en) | 2006-03-08 | 2012-05-08 | Danco Laboratories Llc | Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders |
| JP2008012281A (ja) * | 2006-06-05 | 2008-01-24 | Koritsu Shoji:Kk | 挿入補助器具 |
| KR20070116538A (ko) * | 2006-06-05 | 2007-12-10 | 유겐가이샤 코리츠 쇼지 | 삽입 보조 기구 |
| CZ300424B6 (cs) * | 2006-06-20 | 2009-05-13 | Pliva - Lachema A. S. | Farmaceutická kompozice pro perorální podání |
| ES2814343T3 (es) | 2006-10-24 | 2021-03-26 | Allergan Pharmaceuticals Int Ltd | Composiciones y métodos para suprimir las proliferaciones endometriales |
| CA2682752C (en) * | 2007-04-05 | 2015-07-07 | University Of Kansas | Rapidly dissolving pharmaceutical compositions comprising pullulan |
| SI2148681T1 (sl) | 2007-04-20 | 2016-07-29 | Preglem S.A. | Selektivni modulatorji progesterona v zdravljenju maternične krvavitve |
| CA2700253A1 (en) | 2007-09-20 | 2009-03-21 | Bio-Pro Medical Ltd. | Compositions and means for treating uterine leiomyomata, leiomyoma, myoma, uterine fibroids, endrometriosis, adenomyosis and related disorders by mifepristone |
| TWI477276B (zh) | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
| US20130066302A1 (en) | 2009-09-29 | 2013-03-14 | MEDIMETRICS Personalized Drug Delivery B.V. | Intrauterine electronic capsule for administering a substance |
| UA113283C2 (xx) | 2010-12-23 | 2017-01-10 | 19-норстероїди і їх застосування для лікування прогестеронзалежних станів | |
| DE202011110355U1 (de) | 2011-03-09 | 2014-01-15 | Arstat, Inc. | Behandlung von Uterusmyomen durch intravaginale Verabreichung einer niedrigen Dosis eines selektiven Progesteronrezeptormodulators, eines Antigestagens oder eines Antigestagen-Wirkstoffes |
| UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування |
-
2013
- 2013-05-30 CA CA2872644A patent/CA2872644A1/en not_active Abandoned
- 2013-05-30 EP EP13728632.4A patent/EP2854763B1/en active Active
- 2013-05-30 US US14/403,141 patent/US10328022B2/en not_active Expired - Fee Related
- 2013-05-30 IN IN10548DEN2014 patent/IN2014DN10548A/en unknown
- 2013-05-30 AU AU2013267359A patent/AU2013267359C1/en not_active Ceased
- 2013-05-30 MX MX2014014054A patent/MX363640B/es unknown
- 2013-05-30 UA UAA201414106A patent/UA114106C2/uk unknown
- 2013-05-30 KR KR1020147032210A patent/KR102127348B1/ko not_active Expired - Fee Related
- 2013-05-30 ES ES13728632T patent/ES2701400T3/es active Active
- 2013-05-30 CN CN201380028413.4A patent/CN104334158B/zh not_active Expired - Fee Related
- 2013-05-30 SG SG10201704858PA patent/SG10201704858PA/en unknown
- 2013-05-30 JP JP2015515205A patent/JP6341910B2/ja not_active Expired - Fee Related
- 2013-05-30 WO PCT/US2013/043447 patent/WO2013181449A1/en active Application Filing
- 2013-05-30 EA EA201492290A patent/EA030444B1/ru unknown
- 2013-05-30 NZ NZ702467A patent/NZ702467A/en not_active IP Right Cessation
- 2013-05-30 BR BR112014029131-4A patent/BR112014029131B1/pt not_active IP Right Cessation
- 2013-05-30 MX MX2019003467A patent/MX382986B/es unknown
- 2013-05-30 SG SG11201407397WA patent/SG11201407397WA/en unknown
-
2014
- 2014-11-02 IL IL235450A patent/IL235450B/en active IP Right Grant
- 2014-11-11 ZA ZA2014/08262A patent/ZA201408262B/en unknown
- 2014-11-11 PH PH12014502516A patent/PH12014502516A1/en unknown
- 2014-11-25 CO CO14259346A patent/CO7141411A2/es unknown
- 2014-11-27 CL CL2014003232A patent/CL2014003232A1/es unknown
- 2014-12-09 CR CR20140567A patent/CR20140567A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407397WA (en) | Formulations and methods for vaginal delivery of antiprogestins | |
| SG11201408174UA (en) | Antibody formulation | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201811580SA (en) | Compositions, devices, and methods for the treatment of alcohol use disorder | |
| SG11201811549UA (en) | Boronic acid derivatives and therapeutic uses thereof | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
| SG11201407340YA (en) | Treatment of myelosuppression | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201407961WA (en) | Risperidone or paliperidone implant formulation | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201902531QA (en) | Liquid pharmaceutical composition | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201907159SA (en) | Treatment of hidradenitis suppurativa | |
| SG11201902974PA (en) | Combination of a pd-1 antagonist and eribulin for treating urothelial cancer | |
| SG11201408509PA (en) | Racecadotril lipid compositions | |
| SG11201806140SA (en) | Stable liquid gonadotropin formulation |